SCHEMBL534155

SCHEMBL534155

O=C(O)CNc1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.56
FABP1 P07148 1/20 0.56
FABP6 P51161 1/20 0.56
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
PKM P14618 2/20 0.55
CXCR4 P61073 1/20 0.53
CYP2D6 P10635 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ADORA3 P0DMS8 1/20 0.51
PIM1 P11309 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA2B P29275 1/20 0.51
ADORA1 P30542 1/20 0.51
FLT3 P36888 1/20 0.51
PIM3 Q86V86 1/20 0.51
AURKB Q96GD4 1/20 0.51
FDPS P14324 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL360682 1.00 GAA (0.56) GAAFABP1FABP6NPC1RAB9A
SCHEMBL9722609 0.86 GAA (0.58) GAAFABP1FABP6NPC1RAB9A
Hydrochloric Acid SCHEMBL14914649 0.84 ITGB3 (0.61) GAAFABP1FABP6NPC1RAB9A
SCHEMBL13589538 0.83 GAA (0.55) GAAFABP1FABP6NPC1RAB9A
SCHEMBL2857962 0.83 GAA (0.55) GAAFABP1FABP6NPC1RAB9A
Hydrochloric Acid SCHEMBL7494264 0.82 GAA (0.50) GAAFABP1FABP6NPC1RAB9A
SCHEMBL3615506 0.81 GAA (0.53) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL243759 0.81 ITGB3 (0.63) GAAFABP1FABP6NPC1RAB9A
SCHEMBL28664986 0.81 GAA (0.53) GAAFABP1FABP6NPC1RAB9A
SCHEMBL5845136 0.81 ITGB3 (0.55) GAAFABP1FABP6NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114324663-B Method for detecting lornoxicam-related substances 北京金城泰尔制药有限公司 2023-08-15 CN claimed
CN-114324663-A Method for detecting lornoxicam related substances 北京金城泰尔制药有限公司 2022-04-12 CN claimed
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 EP claimed
CN-102448940-B For the medical composition of glaucomatous treatment or prevention UBE INDUSTRIES, LTD. (JP) 2015-10-21 CN claimed
CN-103965099-A Pyridylaminoacetic Acid Compound UBE INDUSTRIES 2014-08-06 CN claimed
CN-101970410-B Pyridylaminoacetic acid compounds UBE INDUSTRIES 2014-06-25 CN claimed
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE INDUSTRIES, LTD. (JP) 2014-04-24 US claimed
US-8648097-B2 Pyridylaminoacetic acid compound UBE INDUSTRIES, LTD. (JP) 2014-02-11 US claimed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US claimed
CN-102448940-A Pharmaceutical composition for treating or preventing glaucoma UBE INDUSTRIES 2012-05-09 CN claimed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP claimed
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE CORPORATION (JP) 2011-03-03 US claimed
CN-101970410-A Pyridylaminoacetic acid compounds UBE INDUSTRIES 2011-02-09 CN claimed
EP-2264009-A1 PYRIDYLAMINOACETIC ACID COMPOUND Ube Industries, Ltd. (JP) 2010-12-22 EP claimed
EP-0966454-B1 DISUBSTITUTED BICYCLIC HETEROCYCLES, THEIR PRODUCTION AND USE AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2003-05-07 EP claimed
US-12636367-B2 Pharmaceutical composition containing pyridylaminoacetic acid compound SANTEN PHARMACEUTICAL CO., LTD. (JP) 2026-05-26 US disclosed
US-12636367-B2 Pharmaceutical composition containing pyridylaminoacetic acid compound SANTEN PHARMACEUTICAL CO., LTD. (JP) 2026-05-26 US disclosed
EP-0017009-B1 DYES AND TINTS BASED ON OPTIONALLY SUBSTITUTED 2-AMINO-5-IMINOPYRROLENINES BAYER AG (DE) 1983-12-28 EP disclosed
EP-0017009-A2 Dyes and tints based on optionally substituted 2-amino-5-iminopyrrolenines BAYER AG (DE) 1980-10-15 EP disclosed
US-4088816-A BACTERICIDES E. R. SQUIBB & SONS, INC. (US) 1978-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 GAA 2639/4885FABP1 2742/4885FABP6 1686/4885
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 GAA 2602/4885FABP1 2819/4885FABP6 1687/4885
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 GAA 1887/4885FABP1 1192/4885FABP6 850/4885
US-12636367-B2 Pharmaceutical composition containing pyridylaminoacetic acid compound PHOSPHO1, PCCA, PGAM1 GAA 541/4885FABP1 2434/4885FABP6 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.